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Abstract 31 
The gut microbiome is composed of approximately 1013–1014 microbial cells and viruses that 32 
exist in a symbiotic, bidirectional communicative relationship with the host. Bacterial functions in 33 
the gut have an important role in healthy host metabolic function, and dysbiosis can contribute 34 
to the pathology of many medical conditions. Alterations in the relationship between gut 35 
microbiota and host have gained some attention in mental health, as new evidence supports the 36 
association of gut bacteria to cognitive and emotional processes. Of interest, illnesses such as 37 
major depressive disorder are disproportionately prevalent in patients with gastrointestinal 38 
illnesses such as inflammatory bowel disease, which pathologically has been strongly linked to 39 
microbiome function. Not only is the microbiome associated with the disease itself, but it may 40 
also influence the effectiveness or adverse effects associated with pharmacologic agents used 41 
to treat these disorders. This field of study may also provide new insights on how dietary agents 42 
may help manage mental illness both directly as well as though their influence on the 43 
therapeutic and adverse effects of psychotropic agents. 44 
 45 
 46 
The human microbiome is primarily composed of 10-100 trillion bacterial symbionts that are 47 
commensal to our gut, mucosal surfaces, and skin.1 These microbes greatly outnumber our 48 
somatic and germ cells by an estimated 10-fold.1 Aside from variation in our genomic DNA, we 49 
understand that the collective genomic content of our gastrointestinal microbiome profiles also 50 
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contributes to human diversity1,2. Although the gut microbiome actually consists of a variety of 51 
microorganisms, such as commensal fungi, viruses, protozoa, and parasites, the vast majority 52 
of work focuses on bacterial colonizers and will be the focus of this review. The bacterial 53 
component of gut microbiota is composed of more than 1000 phylotypes (organisms classified 54 
based on evolutionary relationships), predominantly obligate anaerobes, with Firmicutes and 55 
Bacteroidetes representing more than 90% of the total microbiota3. Gut microbiota structure and 56 
function (the metagenome) is influenced by a variety of factors, including host physiology, diet, 57 
antimicrobials medications, infections, and environment. 58 
Although microbiome research is still developing, there is also a growing amount of evidence to 59 
support the effect of microorganisms on cognitive and emotional processes. This review 60 
summarizes the role of the microbiome on mental illness, focusing on the interaction of the 61 
microbiome and pharmacologic management of psychiatric disease. 62 
Microbiome in the Gut-Brain Axis 63 
The gut-brain axis is a term that defines the bidirectional communication between an individual’s 64 
microbiome and brain, and has become a topic of interest in psychiatry and neuroscience. 65 
Communication from the gut to brain and the brain to gut can occur by neural, hormonal, or 66 
immunologic mechanisms. The ubiquitous presence of neuroendocrine hormones in both 67 
mammalian and nonmammalian systems has been recognized for decades. Bacterially 68 
produced neuroactive compounds include catecholamines, such as norepinephrine and 69 
dopamine, and γ-aminobutyric acid (GABA), histamine, serotonin, and acetylcholine, which have 70 
known roles in a majority of mental illnesses as well as in the mechanisms of action of 71 
psychiatric drugs4. Remarkably, the complete identical biosynthetic pathway for catecholamines 72 
was found in bacteria, which led to the hypothesis that mammalian cell-to-cell signaling 73 
systems, such as neuroendocrine pathways, are derived from late horizontal gene transfer from 74 
bacteria5. Not only do certain species of endogenous bacteria produce these chemicals, but 75 
some bacteria possess receptors to these neuroactive compounds, which suggests that these 76 
compounds not only facilitate interbacterial communication but also mediate communication 77 
from the host6. This intersection of neurobiology and microbiology has been termed microbial 78 
endocrinology.  79 
Gut-brain communication can be mediated in part through enteric, vagal, and central nervous 80 
pathways7. The enteric nervous system (ENS) is embedded into the lining of the intestinal tract 81 
from the esophagus to the colon and governs the function of the gastrointestinal system. 82 
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Despite considerable innervation from the autonomic nervous system, it operates largely 83 
independently of the central nervous system (CNS) and is sometimes referred to as the “second 84 
brain”7. Neurochemicals produced by gut microbiota from the food we eat can directly interact 85 
with receptors found on components of the ENS and can influence the brain via ENS-CNS 86 
communication through the various pathways 8.  87 
The microbiome plays a critical part in the development of the immune response of the intestinal 88 
endothelium and the blood-brain barrier (BBB) system, as shown by work in germ-free mice. 89 
Compared to their conventionally housed counterpart, germ-free mice have stunted 90 
development of gut-associated lymphoid tissue, which is critical in pathogen recognition9. Germ-91 
free mice have also exhibited increased BBB permeability compared to conventionally raised 92 
mice10. Intestinal and BBB integrity can be restored when germ-free mice are colonized with 93 
intestinal microflora. Psychiatric disorders have been linked to the immune system, and an 94 
emerging concept is that gut bacteria may be able to influence the emotional state of the host 11. 95 
It is thought that a commonality between psychiatric illness and the gut may reside in 96 
inflammatory pathways. Indeed, high rates of comorbid depression have been found in patients 97 
with inflammatory disease states such as inflammatory bowel disease and rheumatoid 98 
arthritis12,13. 99 
Understanding the Gut-to-Brain Connection Through Lipids 100 
Short-chain fatty acids (SCFAs) are the major metabolic products of intestinal bacteria derived 101 
from the fermentation of carbohydrates and proteins in the gut14. The main SCFAs produced in 102 
the gut are acetic acid, propionic acid, and butyric acid, which come from dietary intake15. 103 
SCFAs interact with the human body by a number of different mechanisms, including mediation 104 
of colonic epithelial cell growth, hepatic control of lipids and carbohydrates, gene expression, 105 
and energy sources for a wide array of tissues. Both propionic acid and butyric acid have been 106 
shown to be ligands for receptors involved in host energy homeostasis and inflammatory 107 
responses16. SCFAs can cross the BBB and might be environmental factors that contribute to 108 
neurodevelopment disorders such as autism spectrum disorders17. Recent work has highlighted 109 
the role of SCFAs and their regulation of immune responses by their effects on T cells, 110 
neutrophils, and colonocytes. Importantly, SCFAs have been shown to induce both effector and 111 
interleukin-10 T-regulatory cells, depending on the cytokine condition and immunologic context 112 
18,19. 113 
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Bile acids are not only a known contributor to drug pharmacokinetics but are also a regulator of 114 
gut microbiome composition20. Formed in the liver, bile acids account for the majority of 115 
cholesterol turnover in the body. Bile acids form micelles in bile and are excreted in the small 116 
intestine after eating, where they are an essential component required for the absorption of 117 
lipophilic vitamins, fat, and drugs. The gut microbiome is capable of producing secondary bile 118 
acids, such as deoxycholic acid and lithocholic acid, that affect host metabolic processes, drug 119 
metabolism, and immune response21,22. Bile acids mediate these processes through the 120 
activation of receptors such as the farnesoid X, pregnane X, vitamin D (VDR), and TGR5 121 
receptors23,24. Activation of the VDR exhibits wide range of immunomodulatory effects, and VDR 122 
ligands have been shown to reduce messenger RNA (mRNA) expression and decrease plasma 123 
concentrations of proinflammatory cytokines2425. Bile acids also have antimicrobial properties 124 
despite the microbiome’s critical role in their biotransformation; thus, a dynamic equilibrium 125 
exists between the microbiome and the bile acid pool26.  126 
Cometabolism of Drugs by Host and Gut Bacteria 127 
The pharmacokinetics of orally administrated drugs can be complicated and dependent on 128 
measures such as the chemical properties and environmental risk parameters specific for each 129 
drug. Knowledge of how human genetics affect drug pharmacokinetics and pharmacodynamics 130 
has further advanced our understanding of inter-individual variations in drug efficacy and 131 
adverse effects, but much variation remains unexplained. An important but sometimes 132 
overlooked contributor to drug metabolism is the gut microbiota, which expands the metabolic 133 
processes of these compounds beyond that of mammalian encoded enzymes. 134 
Microbiome-mediated reactions in the gut tend to be dominated by reduction or hydrolysis 135 
reactions whereas mammalian metabolism shows a greater propensity for oxidation and 136 
conjugation27. Gut microbiota have been shown to participate in the reductive metabolism of 137 
psychotropic medications such as the benzodiazepine clonazepam28. Risperidone, an atypical 138 
antipsychotic, has been shown in postmortem studies to undergo gut-mediated isoxazole 139 
scission,29 and studies with levodopa, a mainstay in the treatment for Parkinson’s disease, show 140 
that the presence of Helicobacter pylori is associated with decreased plasma levels of the 141 
drug30. Although the pharmacokinetics of these medications may, in part, be altered by the 142 
microbiome, there are currently no defined clinical consequences of these occurrences. The gut 143 
microbiota can also indirectly contribute to xenobiotic metabolism by altering gene expression of 144 
hepatic enzymes that aid in the metabolism and detoxification of drugs outside of the gut. 145 
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Studies in colonized and germ-free rats (rats cultivated with no intestinal microbiota) showed 146 
that the microbiome affects hepatic concentration of both phase I and phase II metabolizing 147 
enzymes, which are responsible for transformation of the majority of prescribed medications 148 
31,32.  149 
Microbiome, Inflammation, and Mood 150 
Changes in proinflammatory and cell-mediated immune cytokines have been thoroughly 151 
documented in psychiatric diseases such as major depressive disorder (MDD). In fact, in 152 
addition to genetic and environmental factors, a robust association has been defined for MDD, 153 
immune response, and inflammation33,34. Evidence suggests that antidepressants such as the 154 
tricyclic antidpessants and selective serotonin reuptake inhibitors (SSRIs) may function to 155 
normalize cytokine levels, and this may be an additional therapeutic mechanism secondary to 156 
their effect on neurotransmitters33,35. Several studies have examined the effects of 157 
antidepressants on bacterial endotoxin lipopolysaccharide (LPS)-induced inflammation and 158 
depressive symptoms in animals. In rodents, pretreatment with SSRIs (fluoxetine or paroxetine) 159 
or serotonin-norepinephrine reuptake inhibitors (venlafaxine and duloxetine) reduced LPS-160 
induced inflammation and depressive-like behaviors36.  161 
Few studies have examined whether an increased gastrointestinal permeability with an 162 
increased translocation of LPS from gram-negative bacteria may play a role in the 163 
pathophysiology of MDD and other mental illnesses. One study in humans examined levels of 164 
serum antibodies against LPS of gram-negative enterobacteria and found higher levels in 165 
patients with MDD than in controls37. Alterations in gut epithelial permeability in patients with 166 
autism and schizophrenia has been described but without conclusive results38. In animals, acute 167 
and chronic stress has been shown to lead to increased gut permeability and bacterial 168 
translocation39,40. In these studies, the therapeutic benefits, such as reduced stress-induced 169 
corticosterone level, anxiety, and depression-related behaviors, were obtained through the 170 
administration of probiotics. The therapeutic benefits of adjunct therapy with minocycline and 171 
doxycycline have been explored in both animal and human studies for MDD and 172 
schizophrenia41-43. Minocycline has antioxidant, anti-inflammatory, and neuroprotective 173 
properties that are not related to its antimicrobial properties but mirror many of the deficits 174 
observed in MDD44,45.  175 
Microbiome, Obesity, and Cardiovascular Disease in the Mental Health Population 176 
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Longitudinal studies following the introduction of atypical antipsychotics antipsychotics(AAPs) 177 
have noted the growing contribution of cardiac and metabolic disease to increased mortality in 178 
subjects with schizophrenia.46 Recent data suggest that the standardized mortality ratio for 179 
cardiac disease in these subjects is increasing compared with the general population47,48. Due 180 
to the wealth of data that links changes in the microbiome to obesity and metabolic syndrome, 181 
the role of the microbiome in AAP–associated metabolic risk is currently being investigated in 182 
animal models. 183 
A study of olanzapine use in rats demonstrated that treatment had significant effects on a 184 
number of physiologic, inflammatory, and microbial parameters and that many, but not all, were 185 
more pronounced in females compared with males49. Specific microbiome alterations in 186 
olanzapine-treated female rats included dose-dependent increased levels of Firmecutes, 187 
decreased levels of Bacteriodetes species, and overall decreased biodiversity. These 188 
observations were replicated in male rats but only at higher doses. In a follow-up study 189 
performed in female rats, coadministration of antibiotics attenuated the physiologic and 190 
inflammatory effects of olanzapine use50. A recent study in germ-free mice determined that gut 191 
bacteria were not only necessary but sufficient for olanzapine-mediated weight gain51. As seen 192 
in previous studies, colonized mice treated with olanzapine showed a shift in gut microbiota 193 
toward an “obesogenic bacterial profile”.52 Finally, in an in vitro model, olanzapine was 194 
determined to have antimicrobial activity against enteric bacterial strains.51 In all, these studies 195 
make a strong case for the translation of these types of studies to humans.  196 
Personalized Management of Gut Microbiota 197 
Currently, interest in exploring probiotics as a component of nutrition-based health is 198 
widespread. Probiotics are currently defined as a dietary supplement containing live bacterial 199 
cultures that is taken orally in adequate quantities to exert a health benefit. Although many 200 
bacteria are advertised as probiotics, data show that the in vivo effects of different species vary 201 
greatly, and few have been thoroughly investigated. Derived benefits from probiotic 202 
microorganisms are due to a number of different actions, including conferring protection against 203 
pathogenic organisms and modulation of the immune response, and the actions of microbial-204 
derived metabolic products53. Evidence that using probiotics to affect human behavior is limited, 205 
but there are data that support its use as an adjuvant treatment in mental health. 206 
Desbonnet et al. assessed potential benefits of the probiotic Bifidobacterium infantis compared 207 
with the SSRI citalopram on mood using a rat maternal separation model.54 In this study, 208 
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maternally separated rats were chronically treated with Bifidobacterium infantis or citalopram. 209 
Assessments made were motivational state, as measured by a forced swim test, cytokine 210 
concentrations in whole blood samples, monoamine levels in the brain, and central and 211 
peripheral hypothalamic-pituitary-adrenal axis measures. For the control group of nontreated 212 
rats, maternal separation reduced swim behavior (indicating a depressed-like behavior) and 213 
decreased mobility as demonstrated by the forced swim test. Decreased norepinephrine levels 214 
were measured in the brain in addition to greater proinflammatory cytokine and amygdala 215 
corticotropin-releasing factor mRNA levels. Probiotic treatment resulted in improvement of mood 216 
deficiencies in addition to normalization of cytokine levels and basal norepinephrine levels, 217 
which was comparable to the effects of citalopram. 218 
Another study by Bravo et al. investigated the impact of Lactobacillus rhamnosus on behavior 219 
and central GABA receptors in mice.40 Probiotic-treated mice exhibited reduced anxiety 220 
symptoms and altered cerebral expression of both GABA type A and GABA type B receptors 221 
compared with mice treated with inactive broth. A subset of animals underwent a vagotomy and 222 
was treated with either the probiotic or inactive broth. Vagtoimized mice treated with a probiotic 223 
did not show a decrease in anxiety indicating that the vagus may mediate behavioral and 224 
neurochemical effects of L. rhamnosus.  225 
Table 1 provides a summary of preclinical and clinical studies examining microbiomes in 226 
animals or humans with behavioral and psychological disorders. 227 
Perspective and Future: Impact of Host Microbiome on Personalized Medicine 228 
Advances in next-generation sequencing and culture-independent approaches to study the 229 
microbiome have led to a new understanding of the microbiome’s involvement on host 230 
physiology and disease. The most common method of studying microbiome biodiversity and 231 
structure is by sequencing hypervariable regions of the gene encoding the small ribosomal 232 
subunit known as 16S66. As many of the anaerobic species that inhabit the gut are not 233 
culturable, we may find that composition data may not be sufficient to define the role of the 234 
microbiome in health and disease. Perhaps even more insightful, culture-independent methods 235 
such as shotgun sequencing of the metagenome are now employed to study both the 236 
composition and the functionality of processes occurring in the gut67.  237 
Conclusion 238 
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Consideration of the human gut microbial composition and function will be a necessary part of 239 
future personalized medicine strategies. There is a great potential in examining the microbiome 240 
to develop diagnostic markers of disease and to take advantage of therapeutic strategies that 241 
will maximize the benefice of a healthy gut structure. Currently, most data describing the 242 
importance of the microbiome in psychiatric illness and pharmacologic management are from ex 243 
vivo or animal preclinical models. Biological validation of these methods on large human cohorts 244 
will be necessary to demonstrate the strength and clinical utility of these types of predictors and 245 
therapeutic management of disease.  246 
 247 
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 248 
Table 1. Preclinical and Clinical Studies Examining Microbiomes in Animals or Humans with Behavioral and Psychological Disorders 
Reference Model Probiotic Intervention or Other Method Conclusions 
Preclinical studies 
   
 
Germ-free  
  
Neufeld et al. (55) 
mouse 
(female) 
Comparison of  germ-free vs SPF mice 
Basal behavior for germ-free mice vs SPF mice was interpreted as 
anxiolytic; increased BDNF mRNA in hippocampus of germ-free 
animals 
Goehler et al. (56) mouse Camphylobacter jejuni Increased anxiety-like behavior and increased markers of activation 
within the limbic structures in the brain 
Bravo et al. (40) mouse Lactobacillus rhamnosus 
Induced region-dependent alterations in GABA mRNA in the brain and 
reduced stress-induced corticosterone level and anxiety- and 
depression-related behavior that was not seen in vagotimized mice 
Steinberg et al. (57) mouse 
Lactobacillus acidophilus L36 or Lactobacillus 
salivarius L38  
L36 increased the expression of Th2 cytokines (IL-5, IL-6 and TGF-β1) 
and Th17 (IL-17a, TNF-α and IL-6) inflammatory response 
 
Conventional  
  
Zareie et al. (58) rat 
Lactobacillus helveticus and Lactobacillus 
rhamnosus Intervention prevented chronic stress-induced intestinal abnormalities 
 Desbonnet et al. 
(54)  
rat 
Bifidobacterium infantis 
Decreased depressive-like behavior in maternal separation model 
Ait-Belgnaoui et al. 
(59) 
rat (female) 
Lactobacillus farciminis Treatment attenuated the HPA response to acute stress 
    
Clinical studies 
   
Tillisch et al. (60) 
human 
(female) 
FMPP; Bifidobacterium animalis , Streptococcus 
thermophiles, Lactobacillus bulgaricus, and 
Lactococcus lacti 
Intervention affected activity of brain regions that control central 
processing of emotion and sensation 
Benton et al. (61) human Lactobacillus casei Improved mood 
Messaoudi et al. 
(62) 
human and 
rat 
Lactobacillus helveticus and Bifidobacterium 
longum 
Beneficial effects on anxiety and depression and showed reduced 
urinary levels of cortisol 
Schmidt et al. (63) human Prebiotics 
Intervention associated with lower cortisol levels at awakening and 
improved attention to positive stimuli compared with negative stimuli in 
an emotional categorization task and in an emotional recognition task 
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Rao et al. (64) human Lactobacillus casei Decreased anxiety in patients with chronic fatigue syndrome 
Tomasik et al. (65) 
humans with 
schizophrenia  
Lactobacillus rhamnosus GG and Bifidobacterium 
lactis Bb12. 
14 weeks of probiotic add-on treatment significantly reduced levels of 
vWF and increased levels of MCP-1, BDNF, RANTES, and MIP-1 beta 
with borderline significance (p= 0.08) 
SPF = specific pathogen-free; BDNF = brain-derived neurotrophic factor; mRNA = messenger RNA; GABA=γ-aminobutyric acid; Th = T helper; IL = interleukin; TGF = 
transforming growth factor; TNF- α = tumor necrosis factor α; HPA = hypothalamic-pituitary-adrenal; FMPP = fermented milk product with probiotic; prebiotics = 
oliogosaccharides that can promote growth of beneficial commensal bacteria; vWF = von Willebrand factor; MCP-1 = monocyte chemotactic protein-1; RANTES = a 
cytokine that is a member of the IL-8 superfamily of cytokines; MIP-1= macrophage inflammatory protein-1. 
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